Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, antibodies to mammalian Interleukin 7 receptors and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.

Abstract: Mammalian granulocyte-colony stimulating factor (G-CSF) receptor proteins, DNAs and expression vectors encoding mammalian G-CSF receptors, and processes for producing mammalian G-CSF receptors as products of recombinant cell culture, are disclosed.

Abstract: A method for detecting anti-Leishmania parasite antibodies to a 230 kDa antigen present in Leishmania chagasi and Leishmania donovani is disclosed which comprises obtaining a sample from an individual, contacting the sample with a recombinant K39 repeat unit antigen comprising the amino acid sequence as shown in SEQ ID NO:3, and detecting the presence of anti-Leishmania parasite antibodies in the sample which bind to the recombinant K39 repeat unit antigen.

Abstract: A fusion protein which comprises MGF and IL-3. Such fusion proteins have enhanced biological activity.

Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to Tumor Necrosis Factor, thereby functioning as Tumor Necrosis Factor antagonists. Also disclosed are processes for preparing isolated viral protein cytokine antagonists.

Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.

Abstract: The present invention provides an isolated DNA sequence encoding soluble and membrane bound forms of a mammalian IgA Fc receptor, as well as recombinant expression vectors and host cells suitable for expressing the protein.

Abstract: Substantially purified and homogeneous soluble human interleukin-1 receptor (shuIL-1R) proteins, DNA encoding the shuIL-1R proteins and pharmaceutical compositions containing the shuIL-1R proteins are described.

Abstract: Ligand reagents are disclosed which consist essentially of recombinant hyperglycosylated cytokines, expressed in yeast, which are purified and conjugated to various functional moieties, for example, biotin groups, via oligosaccharide residues. Methods of using such ligand reagents are also disclosed.

Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.

Abstract: Cloning and expression of DNA segments encoding bovine IL-1.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.

Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.

Abstract: Isolated and purified Interleukin-4 Binding Protein-.gamma. (IL-4bp.gamma.) and methods for obtaining isolated and purified IL-4bp.gamma..

Abstract: Ligand reagents are disclosed which consist essentially of recombinant hyperglycosylated cytokines, expressed in yeast, which are purified and conjugated to various functional moieties, for example, biotin groups, via oligosaccharide residues.

Abstract: Wound healing compositions comprising IL-1.alpha. and IL-1.beta. proteins in a physiologically acceptable hydrophilic vehicle are used to promote wound healing.

Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.

Abstract: Subjects suffering from infectious diseases are treated by direct administration of therapeutically-effective quantities of granulocyte-macrophage colony stimulating factor employed by itself or in conjunction with an antibiotic or a sulfonamide or other immunologically effective therapeutic agents. Homogeneous granulocyte-macrophage colony stimulating factor for use in treatment in bacterial diseases is prepared by recombinant DNA techniques and then purified to homogeneity by reverse phase high-performance liquid chromatography so that it may be safely administered to subject's suffering from infectious diseases.

Abstract: The present invention provides a pharmaceutical compositions comprising as active ingredients certain truncated purified human IL-3(Pro.sup.8 Asp.sup.15 Asp.sup.70) analog proteins expressed by transformed yeast of the species Saccharomyces cerevisiae, which when administered to a primate do not result in detectable urticaria.

Abstract: A process for preparing bovine interleukin I.beta. (bIL-1.beta.) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-1.beta. under conditions suitable for the expression of bIL-1.beta. and recovering bIL-1.beta..

Abstract: Cloning and expression of DNA segments encoding bovine GM-CSF, and processes for producing recombinant bovine GM-CSF as a product of recombinant cell culture, are disclosed.